Clinical trials
Follow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
FcgRIIb agonist antibody
- Development stage
- Preclinical
- Lead developer
- Seismic Therapeutics
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics
- Administration
- Subcutaneous, Intravenous
01
Overview
FcgRIIb agonist antibody refers to a class of therapeutic monoclonal antibodies designed to selectively target and activate Fc gamma receptor IIb (FcgRIIb, also known as CD32B), the sole inhibitory receptor within the Fc gamma receptor family [vkag141.035]. Co-ligation of FcgRIIb with activating receptors triggers inhibitory signaling (such as SHIP-1 recruitment) that downregulates immune cell activation [vkag141.035]. Developing selective agonists has historically been challenging due to the 96% sequence identity between the extracellular domains of FcgRIIb and the activating receptor FcgRIIa [vkag141.035]. Seismic Therapeutic has utilized its machine learning-enabled IMPACT platform to discover selective FcgRIIb agonist antibodies that avoid activating FcgRIIa, demonstrating the ability to reduce antigen-specific antibody responses in preclinical models of autoimmune and inflammatory diseases [vkag141.035].
- Other names
- FcγRIIb agonist antibody
02
Targets
FCGR2A (Low affinity immunoglobulin gamma Fc receptor II-a)FCGR2B (Fc gamma receptor IIB)PDCD1 (Programmed cell death protein 1 receptor)
Beyond the preview
Go deeper on FcgRIIb agonist antibody.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Explore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Trace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Explore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Compare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Connect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on FcgRIIb agonist antibody.